Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

BACKGROUND: Immune checkpoint inhibitors monotherapy has been studied in patients with advanced biliary tract cancer (BTC). The aim of this study was to assess the efficacy and safety of camrelizumab, plus gemcitabine and oxaliplatin (GEMOX) as first-line treatment in advanced BTC and explored the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaofeng, Wu, Xiaofeng, Wu, Hao, Gu, Yanhong, Shao, Yang, Shao, Qianwen, Zhu, Feipeng, Li, Xiao, Qian, Xiaofeng, Hu, Jun, Zhao, Fengjiao, Mao, Weidong, Sun, Jing, Wang, Jian, Han, Gaohua, Li, Changxian, Xia, Yongxiang, Seesaha, Poshita Kumari, Zhu, Dongqin, Li, Huajun, Zhang, Junling, Wang, Guoqiang, Wang, Xuehao, Li, Xiangcheng, Shu, Yongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656907/
https://www.ncbi.nlm.nih.gov/pubmed/33172881
http://dx.doi.org/10.1136/jitc-2020-001240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656907/
https://www.ncbi.nlm.nih.gov/pubmed/33172881
http://dx.doi.org/10.1136/jitc-2020-001240

Ejemplares similares